← Browse by Condition
Medical Condition

pancreatic neuroendocrine tumor

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for pancreatic neuroendocrine tumor sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — pancreatic neuroendocrine tumor Clinical Trials

How many clinical trials are currently recruiting for pancreatic neuroendocrine tumor?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for pancreatic neuroendocrine tumor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pancreatic neuroendocrine tumor?
pancreatic neuroendocrine tumor research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pancreatic neuroendocrine tumor clinical trial?
Eligibility criteria for pancreatic neuroendocrine tumor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Uppsala University 1 trial
SWOG Cancer Research Network 1 trial
Qilu Hospital of Shandong University 1 trial
IRCCS San Raffaele 1 trial

Recruiting Clinical Trials

NCT07273409
Recruiting

Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not

Enrollment
200 pts
Location
Sweden
Sponsor
Uppsala University
View Trial →
NCT05040360 Phase 2
Recruiting

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Enrollment
141 pts
Location
United States, Mexic...
Sponsor
SWOG Cancer Research Network
View Trial →
NCT06041009
Recruiting

Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations

Enrollment
2,100 pts
Location
China
Sponsor
Qilu Hospital of Shandong Univ...
View Trial →
NCT06121622
Recruiting

Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours

Enrollment
70 pts
Location
Italy
Sponsor
IRCCS San Raffaele
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology